USP18 stimulates HCV production and blunts the antiviral effect of IFNα independent of its protease activity

被引：0
|
作者：
Chen, L. [1 ]
Sun, J. [1 ]
Heathcote, J. [1 ]
Edwards, A. [1 ]
McGilvray, I. [1 ]
机构：
[1] Univ Toronto, Toronto, ON M5S 1A1, Canada
来源：
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES | 2010年 / 14卷
关键词：
D O I：
10.1016/S1201-9712(10)02402-1
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
引用
收藏
页码：S1 / S1
页数：1
相关论文
共 27 条
  • [21] The HCVNS3 protease inhibitor SCH 503034 in combination with PEG-IFNα-2b in the treatment of HCV-1PEG-IFNα-2b non-responders:: Antiviral activity and HCV variant analysis
    Zeuzem, S.
    Sarrazin, C.
    Wagner, F.
    Rouzier, R.
    Forestier, N.
    Gupta, S.
    Hussain, M.
    Shah, A.
    Cutler, D.
    Zhang, J.
    JOURNAL OF HEPATOLOGY, 2006, 44 : S35 - S35
  • [22] STRONG ANTIVIRAL ACTIVITY AND SAFETY OF IFN-SPARING TREATMENT WITH THE PROTEASE INHIBITOR BI 201335, THE HCV POLYMERASE INHIBITOR BI 207127 AND RIBAVIRIN IN PATIENTS WITH CHRONIC HEPATITIS C
    Zeuzem, Stefan
    Asselah, Tarik
    Angus, Peter W.
    Zarski, Jean-Pierre H.
    Larrey, Dominique
    Mullhaupt, Beat
    Gane, Edward J.
    Schuchmann, Marcus
    Lohse, Ansgar W.
    Pol, Stanislas
    Benhamou, Yves
    Bronowicki, Jean-Pierre
    Roberts, Stuart K.
    Arasteh, Keikawus
    Zoulim, Fabien
    Heim, Markus H.
    Stern, Jerry O.
    Kukolj, George
    Nehmiz, Gerhard
    Haefner, Carla
    Boecher, Wulf O.
    HEPATOLOGY, 2010, 52 (04) : 876A - 877A
  • [23] GALLIC ACID HAS ANTIVIRAL EFFECT AGAINST HEPATITIS C VIRUS (HCV), WHICH IS MEDIATED BY ITS ANTIOXIDANT ACTIVITY
    Govea Salas, M.
    Rivas Estilla, A. M.
    Morlett Chavez, J. A.
    Lozano Sepulveda, S. A.
    Rodriguez Herrera, R.
    Aguilar Gonzalez, C. N.
    JOURNAL OF HEPATOLOGY, 2014, 60 (01) : S208 - S208
  • [24] Ubiquitin-Specific Protease 2b Negatively Regulates IFN-β Production and Antiviral Activity by Targeting TANK-Binding Kinase 1
    Zhang, Lei
    Zhao, Xueying
    Zhang, Meng
    Zhao, Wei
    Gao, Chengjiang
    JOURNAL OF IMMUNOLOGY, 2014, 193 (05): : 2230 - 2237
  • [25] CONSISTENT RESULTS FOR ANTIVIRAL ACTIVITY AND SAFETY OF SUSTAINED RELEASE INTERFERON-ALPHA-2B (IFN-ALPHA-2B XL) COMPARED TO MARKETED IFN-ALPHA-2B AND ITS PEGYLATED FORM (PEG-IFN-ALPHA-2B) IN TWO PHASE I TRIALS IN HEPATITIS C (HCV) PATIENTS
    Trepo, Christian
    Rouzier, Regine
    Raffonel, Claude
    Maynord-Muet, Marianne
    Belhadi-Tahor, Hofid
    Bourliere, Marc
    Donozzolo, Yves
    Prodat, Pierre
    Berthillon, Pascale
    Guest, Maryline
    Grossot, Julien
    Meyrueix, Rerni
    Nicolas, Florence
    Krovt-Zoff, Roger
    HEPATOLOGY, 2008, 48 (04) : 534A - 534A
  • [26] The positive influence of methotrexate on the mortality of patients with rheumatoid arthritis is partly independent of its effect on disease activity: results of a re-evaluation 18 years after baseline
    Krause, D.
    Gabriel, B.
    Herborn, G.
    Braun, J.
    Rau, R.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2014, 32 (03) : 395 - 400
  • [27] A Phase I/IIa study of safety, tolerability, and pharma-cokinetic profiles of TG-2349, a pan-genotypic HCV protease inhibitor, in healthy East Asian and Caucasian subjects, and its antiviral activity in chronic hepatitis C patients
    Tsai, Chen-En
    Chang, Li-Wen
    Chang, Yu-Ting
    Hsu, Chiung-Yuan
    Chen, Chih-Ming
    Tsai, Cheng-Yuan
    Lin, Chu-Chung
    King, Chi-Hsin R.
    Liu, Chun-Jen
    Chen, Ding-Shinn
    Hsu, Ming-Chu
    HEPATOLOGY, 2013, 58 (06) : 1388A - 1388A
123